Abstract: The invention relates to a nutritional and medicinal oral composition for veterinary use, including a core of complete feed extrudate coated with at least one layer of fat. The layer of fat includes at least one medicinal agent which includes: (i) at least one preconditioned active principle in the form of a solution or a suspension of said active principle in an oily liquid, or (ii) at least one preconditioned active principle in the form of waxy granules.

Abstract: Disclosed is a palatable oral veterinary pharmaceutical composition consisting of an oil suspension of metronidazole and comprising metronidazole in an edible animal, vegetable or mineral oil and the use thereof for treating diarrhea in animals, in particular giardiasis or inflammatory diseases of the digestive tract.

Abstract: The invention relates to a method for producing a nutritional and medicinal oral composition for veterinary use, comprising the following steps: a) providing cores of extruded products of complete feed, and b) coating the cores of extruded products of complete feed provided in step a) with at least one layer of a fatty material comprising at least one medicinal agent, said medicinal agent comprising (i) at least one pre-conditioned active substance in the form of a solution or a suspension of said active substance in an oily liquid, or (ii) at least one pre-conditioned active substance in the form of waxy granulates, at a temperature lower than 40° C.

Abstract: Described herein is an association of at least one phosphate binder, at least one uremic toxin binder, at least one vasoactive antihypertensive agent and at least one antifibrotic agent for the management of progressive renal diseases including chronic kidney diseases (CKD) in domestic carnivores. Specifically, the application describes veterinarian compositions comprising such an association and the use thereof for the treatment of CKD conditions.

Abstract: Described herein is a method of administering mirtazapine via the parenteral route to treat the decrease or loss of appetite and/or other disorders induced by undernutrition in cats.

Abstract: A chewable composition, comprising:—at least one pharmaceutically active ingredient component;—solid components including:—at least one flavor;—at least one disintegrant including at least one non-starch disintegrant;—flowable components including:—a flowable oil;—at least one wetting agent other than water.

Abstract: The invention relates to an oily composition of a non-steroidal anti-inflammatory agent (NSAIA) for parenteral administration with at least one micronized NSAIA, having an acid function and a biocompatible oily vehicle, such that said NSAIA is in the form of a free acid and said composition does not contain any added liquid agent that can solubilize said NSAIA. The invention also relates to the veterinary use thereof.

Abstract: A portable dispensing device for administering fluids intended for animals comprising a backpack with a main compartment delimited by a rear wall configured to come into contact with the back of the user, an outer wall arranged opposite the rear wall and a side wall linking the rear and outer walls, in addition to a flexible pouch containing the fluid to be administered, placed in said main compartment, in which at least the part of the outer wall of the backpack opposite said pouch is made from a rigid material in order to form a shockproof protection and the pouch is removably secured to the rear wall.

Abstract: The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans or animals. In formula (I), R1 and R2 are as defined in claim 1.

Abstract: The invention relates to novel soothing compositions for animals, particularly for cats. It specifically relates to soothing compositions for non-human mammals, comprising between 1% and 50% w/w of at least one fatty acid comprising between 5 and 22 carbon atoms and between 0.01% and 5% w/w of nepetalactone, such that said at least one fatty acid and said nepetalactone are dissolved in a solvent. Said compositions are characterised in that they exhibit soothing properties for stressed animals and are stable for the entire period of use thereof.

Abstract: A chewable composition, comprising at least one pharmaceutically active ingredient component; solid components including at least one flavor, and at least one disintegrant including at least one non-starch disintegrant; flowable components including a flowable oil, and at least one wetting agent other than water.

Abstract: The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.

Abstract: A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent.

Abstract: The invention relates to a chewable object for carnivorous pets. The inventive object (1) is provided with an elongated shape and comprises a chewable, edible and digestible substance. The invention is characterised in that the shape of the object (1) comprises at least two dihedrals (d1, d2) having edges (a1, a2) which essentially extend along the entire length of the object.

Abstract: A porcine circovirus type-2 (PCV2) immunogenic composition includes an antigenic peptide. The antigenic peptide is a non-arginine-rich peptide of a PCV2 open reading frame 2 (ORF2) and/or a recombinant fusion protein having the non-arginine-rich peptide of the PCV2 ORF2, a PE peptide, and a KDEL signal peptide. The number of arginines of the non-arginine-rich peptide of the PCV2 ORF2 is not greater than half of the number of arginines of the arginine-rich domain of the N terminal of the PCV2 ORF2.

Abstract: The present invention relates to a veterinary pharmaceutical composition containing torasemide to be used for treating cardiac failure. The torasemide is administered in a daily dose of 0.02 mg/kg to 0.1 mg/kg during long-term treatment.

Abstract: A chewable composition, comprising at least one pharmaceutically active ingredient component; solid components including at least one flavor, and at least one disintegrant including at least one non-starch disintegrant; flowable components including a flowable oil, and at least one wetting agent other than water.

Abstract: The invention relates to a topical veterinary composition for animals. It is characterized in that it comprises, in a physiologically acceptable medium, extracts of boldo Peumus boldus and extracts of meadowsweet Spiraea ulmaria. The invention applies in particular to preventing or treating or to assisting with the control of microbial infections.

Abstract: The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterized in that it further comprises particles at least 50% of which have a mean diameter greater than 250 ?m. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products.

Abstract: The present invention relates to a liquid topical veterinary pharmaceutical composition consisting of fipronil, permethrin at high concentration and pyriproxyfen such that it does not crystallize when it is applied to the coat of an animal, and to the use thereof in the prevention and/or treatment of infestations of domestic animals by external parasites. The present invention also relates to the use of pyriproxyfen as an inhibitor of the crystallization of a liquid formulation comprising fipronil and permethrin at high concentration.